The pros and cons of chemokines in tumor immunology

Trends in Immunology

Volumn 33, Issue 10, 2012, Pages 496-504

  Viola, Antonella ^a   Sarukhan, Adelaida ^b,e   Bronte, Vincenzo ^c   Molon, Barbara ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Chemokines; Tumor; Tumor immunity; Tumor microenvironment

Indexed keywords

ADENOVIRUS VECTOR; CCL1 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCL2; CHEMOKINE RECEPTOR CCL28; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCL13; DOCETAXEL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 4; NEUTRALIZING ANTIBODY; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL HOMING; CHEMOTAXIS; CLINICAL TRIAL (TOPIC); COLON CARCINOMA; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MYELOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; STOMACH CANCER; THYMOMA; TUMOR MICROENVIRONMENT; TUMOR REJECTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CHEMOKINES; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84866762166     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.05.007     Document Type: Review

References (104)

1. Qian B.Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
2. Molon B., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 2011, 208:1949-1962.
3. Schreiber R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
4. Strieter R.M., et al. CXC chemokines in angiogenesis of cancer. Semin. Cancer Biol. 2004, 14:195-200.
5. Romagnani P., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 2001, 107:53-63.
6. Andreu P., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
7. Wendel M., et al. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008, 68:8437-8445.
8. Ohtani H., et al. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J. Pathol. 2009, 217:21-31.
9. Strieter R.M., et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 2006, 42:768-778.
10. Matsumura S., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008, 181:3099-3107.
11. Gutwein P., et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur. J. Cancer 2009, 45:478-489.
12. Ludwig A., et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J. Neurochem. 2005, 93:1293-1303.
13. Ohta M., et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int. J. Oncol. 2005, 26:41-47.
14. Berghuis D., et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J. Pathol. 2010, 223:347-357.
15. Gonzalez-Martin A., et al. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 2011, 71:5455-5466.
16. Nesbeth Y.C., et al. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J. Immunol. 2010, 184:5654-5662.
17. Fridman W.H., et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr. Top. Microbiol. Immunol. 2011, 344:1-24.
18. Scarpino S., et al. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 2000, 156:831-837.
19. Vicari A.P., et al. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin. Cancer Biol. 2004, 14:161-169.
20. Hiraoka N., et al. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2010, 140:310-321.
21. Bromley S.K., et al. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 2008, 9:970-980.
22. Kanagawa N., et al. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int. J. Cancer 2007, 121:2013-2022.
23. Dieu-Nosjean M.C., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26:4410-4417.
24. Coronella J.A., et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 2002, 169:1829-1836.
25. Deola S., et al. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J. Immunol. 2008, 180:1362-1372.
26. Molon B., et al. T cell costimulation by chemokine receptors. Nat. Immunol. 2005, 6:465-471.
27. Salomon I., et al. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 2002, 169:2685-2693.
28. Flanagan K., et al. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell. Immunol. 2004, 231:75-84.
29. Acosta J.C., Gil J. A role for CXCR2 in senescence, but what about in cancer?. Cancer Res. 2009, 69:2167-2170.
30. Zlotnik A., et al. Homeostatic chemokine receptors and organ-specific metastasis. Nat. Rev. Immunol. 2011, 11:597-606.
31. Galvez B.G., et al. Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J. Biol. Chem. 2005, 280:1292-1298.
32. Singh S., et al. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc. Res. 2011, 82:318-325.
33. Facciabene A., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
34. Jacobs J.F., et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol. 2012, 13:e32-e42.
35. Curiel T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
36. Mailloux A.W., et al. NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. Int. J. Cancer 2010, 127:2598-2611.
37. Liu J., et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS ONE 2011, 6:e19495.
38. Iellem A., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 2001, 194:847-853.
39. Sozzani S., et al. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 1998, 92:4036-4039.
40. Stine J.T., et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000, 95:1151-1157.
41. Dwyer J., et al. Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor. Oncogene 2011, 30:190-200.
42. Grisotto M.G., et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J. Clin. Invest. 2006, 116:1264-1273.
43. Nibbs R.J., et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J. Clin. Invest. 2007, 117:1884-1892.
44. Vetrano S., et al. The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 2010, 59:197-206.
45. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
46. Roca H., et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 2009, 284:34342-34354.
47. Loberg R.D., et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006, 8:578-586.
48. Bailey C., et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin. Exp. Metastasis 2007, 24:121-130.
49. Ueno T., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000, 6:3282-3289.
50. Huang B., et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007, 252:86-92.
51. Chioda M., et al. Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev. 2011, 30:27-43.
52. Lesokhin A., et al. Monocytic CCR2+ myeloid derived suppressor cells promote immune escape by limiting activated CD8 T cell infiltration into the tumor microenvironment. Cancer Res. 2012, 72:876-886.
53. Sawanobori Y., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
54. Serbina N.V., Pamer E.G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 2006, 7:311-317.
55. Yang L., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
56. Shields J.D., et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
57. Villablanca E.J., et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 2010, 16:98-105.
58. Shojaei F., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
59. Kowanetz M., et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21248-21255.
60. Granot Z., et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.
61. Qin Z., et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 1998, 4:627-630.
62. Schioppa T., et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10662-10667.
63. Ammirante M., et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
64. Balkwill F.R. The chemokine system and cancer. J. Pathol. 2012, 226:148-157.
65. Borrello M.G., et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14825-14830.
66. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
67. Pivarcsi A., et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19055-19060.
68. Rosenberg S.A., Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(Suppl 2):14639-14645.
69. Bobisse S., et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 2009, 69:9385-9394.
70. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
71. Laning J., et al. Inhibition of in vivo tumor growth by the beta chemokine, TCA3. J. Immunol. 1994, 153:4625-4635.
72. Lavergne E., et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 2004, 173:3755-3762.
73. Nakashima E., et al. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 1996, 13:1896-1901.
74. Dilloo D., et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 1996, 2:1090-1095.
75. Guo J., et al. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 2002, 9:793-803.
76. Sharma S., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 2000, 164:4558-4563.
77. Kirk C.J., et al. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001, 61:8794-8802.
78. Yang S.C., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res. 2004, 10:2891-2901.
79. Yang S.C., et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006, 66:3205-3213.
80. Baratelli F., et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J. Transl. Med. 2008, 6:38.
81. Kar U.K., et al. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS ONE 2011, 6:e18758.
82. Di Stasi A., et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
83. Craddock J.A., et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 2010, 33:780-788.
84. Moon E.K., et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 2011, 17:4719-4730.
85. Hamzah J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
86. Buckanovich R.J., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008, 14:28-36.
87. Boissonnas A., et al. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 2007, 204:345-356.
88. Mukai S., et al. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 1999, 59:5245-5249.
89. Singh S., et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer 2010, 103:1671-1679.
90. Alfonso-Perez M., et al. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J. Leukoc. Biol. 2006, 79:1157-1165.
91. Buonamici S., et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009, 459:1000-1004.
92. Wiley H.E., et al. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 2001, 93:1638-1643.
93. Cunningham H.D., et al. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice. Transl. Oncol. 2010, 3:354-361.
94. Mizukami Y., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11:992-997.
95. Yoo J.Y., et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther. 2008, 15:635-651.
96. Loberg R.D., et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007, 67:9417-9424.
97. Garber K. First results for agents targeting cancer-related inflammation. J. Natl. Cancer Inst. 2009, 101:1110-1112.
98. Vandercappellen J., et al. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008, 267:226-244.
99. Wyckoff J., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64:7022-7029.
100. Gebhardt C., et al. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006, 72:1622-1631.
101. Markiewski M.M., Lambris J.D. Unwelcome complement. Cancer Res. 2009, 69:6367-6370.
102. Wang D., Dubois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
103. Silva J., et al. Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. J. Biol. Chem. 2003, 278:25376-25385.
104. Goswami S., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005, 65:5278-5283.